The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma treated with sunitinib.
Vano Yann-Alexandre
No relevant relationships to disclose
Benoit Beuselinck
No relevant relationships to disclose
Pascal Wolter
No relevant relationships to disclose
Corine Teghom
No relevant relationships to disclose
Debruyne Philip
No relevant relationships to disclose
Alexandra Karadimou
No relevant relationships to disclose
Evelyne Lerut
No relevant relationships to disclose
Paridaens Robert
No relevant relationships to disclose
Patrick Schöffski
Honoraria - GlaxoSmithKline; Pfizer
Stephane Oudard
Honoraria - Amgen; Bayer; Keocyt; Novartis; Pfizer; Roche; Sanofi